الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 118 |  |  |
| | | from | 118 | | |
Abstract
Uveitis is a group of inflammatory ocular diseases that is responsible for 5%–20% of cases of legal blindness in the USA and Europe and up to 25% of cases of blindness in the developing world. The primary goals of NIU treatment are to control inflammation, preserve vision and minimize risk of treatment-related sequelae. Corticosteroids have remained a mainstay of treatment for NIU but are associated with significant limitations. Topical steroid drops have limited intraocular penetration and are used most frequently in anterior uveitis. Systemic corticosteroids, used long term, have well-established systemic side effects, including weight gain, hypertension, hyperglycemia, osteoporosis, and psychiatric disturbances. For these reasons, guidelines and recommendations by expert panels have advised using steroid-sparing immunomodulatory therapy for chronic or severe NIU when long-term treatment with systemic corticosteroids would otherwise be necessary. These immunosuppressive agents carry their own set of systemic risks, such as hepatotoxicity, liver/kidney injury and an increased incidence of certain malignancies. Suprachoroidal (SC) administration of an investigational corticosteroid formulation (triamcinolone acetonide injectable suspension (CLS-TA)) via a microinjector is a minimally invasive, alternative therapeutic approach to macular oedema (MO) associated with NIU. The current study revealed the following outcomes: •Both demonstrated insignificant differences regarding all demographic date. •Visual acuity was significantly improved in both groups following treatment with no significant differences between them. •CMT was significantly reduced in both groups compared to the baseline values. However, suprachoroidal TA injection group was associated with a significant reduction compared to intravitreal TA injection group at the 6 months only. •Suprachoroidal TA injection group was associated with a significant reduction in IOP compared to the baseline value as well as compared to IVTA group at all follow up periods. Glaucoma and cataract were significantly increased among intravitreal TA injection group compared to suprachoroidal TA injection group. Conclusion : In the context of active non-infectious uveitis, the current study revealed that both suprachoroidal TA and intravitreal TA seemed to be associated with comparable efficiency as regards VA and CMT. However, the possibility of (adverse events) cataract and glaucoma as well as rising IOP was significantly associated with intravitreal TA only.